Source: Eur Respir J 2016; 47:1321-1323
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Richeldi Luca. Targeted treatment of idiopathic pulmonary fibrosis: one step at a time. Eur Respir J 2016; 47:1321-1323

Member's Comments

No comment yet.

Related content which might interest you: A first step against idiopathic pulmonary fibrosis Source: Eur Respir Rev 2011; 20: 130-131 Year: 2011 The therapy of idiopathic pulmonary fibrosis: what is next? Source: Eur Respir Rev, 28 (153) 190021; 10.1183/16000617.0021-2019 Year: 2019 Risk prediction and end-points in idiopathic pulmonary fibrosis: one step at a time Source: Eur Respir J 2014; 43: 1237-1239 Year: 2014 Real-life experience with pirfenidon in idiopathic pulmonary fibrosis: Does early treatment start predict better therapy adherence? Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Combination therapy in idiopathic pulmonary fibrosis: the way ahead will be hard Source: Eur Respir J 2015; 45: 1208-1210 Year: 2015 Pirfenidone treatment in idiopathic pulmonary fibrosis: too much of a great expectation Source: Eur Respir J 2012; 40: 794-795 Year: 2012 Mechanisms of treatment response to pirfenidone of idiopathic pulmonary fibrosis (IPF) patients Source: International Congress 2016 – IPF pathogenesis Year: 2016 Pirfenidone treatment in idiopathic pulmonary fibrosis: An Italian case series Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013 A global registry for idiopathic pulmonary fibrosis: the time is now Source: Eur Respir J 2014; 44: 273-276 Year: 2014 Idiopathic pulmonary fibrosis: another step in understanding the burden of this disease Source: Eur Respir J 2016; 48: 26-28 Year: 2016 Does interferon-γ improve pulmonary function in idiopathic pulmonary fibrosis? Source: Eur Respir J 2003 Dec 01;22(6):906-911 Year: 2003 Accelerated variant of idiopathic pulmonary fibrosis: clinical and molecular behaviour Source: Eur Respir J 2007; 30: Suppl. 51, 488s Year: 2007 Targeting interleukin-13 in idiopathic pulmonary fibrosis: from promising path to dead end Source: Eur Respir J, 52 (6) 1802111; 10.1183/13993003.02111-2018 Year: 2018 Idiopathic pulmonary fibrosis: prime time for a precision-based approach to treatment with N-acetylcysteine Source: Eur Respir J, 57 (1) 2003551; 10.1183/13993003.03551-2020 Year: 2021 Initial clinical experience with nintedanib for treatment of idiopathic pulmonary fibrosis (IPF): About 20 cases Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Idiopathic pulmonary fibrosis: time for greater expectations? Source: Eur Respir J, 52 (2) 1801312; 10.1183/13993003.01312-2018 Year: 2018 Efficacy of pirfenidone in idiopathic pulmonary fibrosis: A single center experience Source: International Congress 2016 – IPF: from pathogenesis to treatment II Year: 2016 Octreotide treatment of idiopathic pulmonary fibrosis: a proof-of-concept study Source: Eur Respir J 2012; 39: 772-775 Year: 2012 Severe idiopathic pulmonary fibrosis: what can be done? Source: Eur Respir Rev, 26 (145) 170047; 10.1183/16000617.0047-2017 Year: 2017